EU green light for Roche’s Tecentriq – PharmaTimes
PharmaTimes |
EU green light for Roche's Tecentriq
PharmaTimes Roche has received European Commission approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with … |
